Literature DB >> 14637161

Novel heparan mimetics potently inhibit the scrapie prion protein and its endocytosis.

Oshrat Schonberger1, Lior Horonchik, Ruth Gabizon, Dulce Papy-Garcia, Denis Barritault, Albert Taraboulos.   

Abstract

During prion diseases the normal prion protein PrP(C) is refolded into an abnormal conformer PrP(Sc). We have studied the PrP(Sc) inhibiting activity of a library of synthetic heparan mimetic (HM) biopolymers. HMs are chemically derived dextrans obtained by successive substitutions with carboxymethyl, benzylamide, and sulfate groups on glucose residues. Some HMs eliminated PrP(Sc) from prion-infected cells after a 5 day course at 100 ng/ml and were 15 x potent than pentosan sulfate in this system. The anti-PrP(Sc) activity of HMs correlated with the degree of sulfation but was increased by benzylamidation. HMs did not reduce the synthesis of PrP(C) nor its attachment to lipid rafts, but instead blocked its conversion into PrP(Sc). The anti-PrP(Sc) HMs also prevented the uptake of prion rods by cultured cells. HMs may thus block the interaction of PrP(Sc) with a putative cellular receptor, possibly heparan sulfate. HMs provide an attractive chemical approach for the synthesis of TSE therapeutic and prophylactic reagents.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14637161     DOI: 10.1016/j.bbrc.2003.10.150

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  22 in total

Review 1.  Sulfated glycosaminoglycans in protein aggregation diseases.

Authors:  Kazuchika Nishitsuji; Kenji Uchimura
Journal:  Glycoconj J       Date:  2017-04-11       Impact factor: 2.916

2.  PrPc does not mediate internalization of PrPSc but is required at an early stage for de novo prion infection of Rov cells.

Authors:  Sophie Paquet; Nathalie Daude; Marie-Pierre Courageot; Jérôme Chapuis; Hubert Laude; Didier Vilette
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

3.  Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds.

Authors:  Brandon B Holmes; Sarah L DeVos; Najla Kfoury; Mei Li; Rachel Jacks; Kiran Yanamandra; Mohand O Ouidja; Frances M Brodsky; Jayne Marasa; Devika P Bagchi; Paul T Kotzbauer; Timothy M Miller; Dulce Papy-Garcia; Marc I Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-29       Impact factor: 11.205

Review 4.  Transmission of α-synuclein seeds in neurodegenerative disease: recent developments.

Authors:  Richard J Karpowicz; John Q Trojanowski; Virginia M-Y Lee
Journal:  Lab Invest       Date:  2019-02-13       Impact factor: 5.662

Review 5.  Protein aggregates stimulate macropinocytosis facilitating their propagation.

Authors:  Justin J Yerbury
Journal:  Prion       Date:  2016-03-03       Impact factor: 3.931

Review 6.  Prion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic target.

Authors:  Brandon B Holmes; Marc I Diamond
Journal:  J Biol Chem       Date:  2014-05-23       Impact factor: 5.157

Review 7.  Internalization, axonal transport and release of fibrillar forms of alpha-synuclein.

Authors:  Gregor Bieri; Aaron D Gitler; Michel Brahic
Journal:  Neurobiol Dis       Date:  2017-03-16       Impact factor: 5.996

Review 8.  Heparin-binding Peptides as Novel Therapies to Stop SARS-CoV-2 Cellular Entry and Infection.

Authors:  Omid Tavassoly; Farinaz Safavi; Iman Tavassoly
Journal:  Mol Pharmacol       Date:  2020-09-10       Impact factor: 4.436

Review 9.  Recent advances in prion chemotherapeutics.

Authors:  Valerie L Sim; Byron Caughey
Journal:  Infect Disord Drug Targets       Date:  2009-02

10.  Glypican-1 mediates both prion protein lipid raft association and disease isoform formation.

Authors:  David R Taylor; Isobel J Whitehouse; Nigel M Hooper
Journal:  PLoS Pathog       Date:  2009-11-20       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.